Making it as an oncology biotech in the UK

We speak to R&D experts to find out how oncology biotechs can get the support they need to be successful in the competitive UK ecosystem

There has never been a more exciting – or more daunting – time to be an oncology biotech. Amazing breakthroughs in cancer science mean there’s no shortage of opportunities in this space – but this also results in fierce competition, and cancer researchers face extra challenges on top of the difficulties posed to any biotech operating in the UK.

“It’s very difficult for any biotech to navigate the UK’s complex innovation system right now,” says Dr Kath Mackay, managing director of Alderley Park, the UK’s largest single-site life science campus. “It can be hard for a company to understand who they should be talking to for funding and support. There are a lot of agencies and groups out there, and if you’re new to the field, navigating that and working out what’s best for you can be a challenge.”

She says it’s also important to find the right partners.

 

• Read the full article in pharmaphorum’s Deep Dive digital magazine